Avid Bioservices Inc (CDMO)

[murdockkills]

JOE SHAN (VP/Clin.&Reg. Affairs) – CLINICAL TRIALS:
To expand a bit on what you just said, the initiation of the SUNRISE pivotal Phase III trial in NSCLC was a major event for us, and one that continues to serve as the main focus for our clinical & regulatory teams. As this pivotal trial will involve over 100 clinical sites worldwide that will enroll close to 600 patients, the continued positive & timely execution of tests is paramount to the success of this trial. To that end, we have accomplished a great deal during this past quarter, as the first clinical sites were initiated and with patients already enrolled and being dosed. We also remain on track with our regulatory and ethics approval timeline for rolling out European & Asian-Pacific sites over the next few months.
http://seekingalpha.com/article/2075263-peregrine-pharmaceuticals-management-discusses-q3-2014-results-earnings-call-transcript